With the acquisition of Manhattan Isotope Technology, Positron gains immediate value to provide a credible and viable radioisotope processing plan, access to existing non-DOE isotope supply, supply chain management, and radioactive waste solutions for the Company. MIT has the intellectual property, expertise and facilities needed to accelerate Positron’s plans for securing the isotope supply channel, thus bringing the company one step closer to offering a full PET solution for the nuclear cardiology industry and becoming the authority in radioisotope production and disposal.
Company Overview
Manhattan Isotope Technology, LLC is a radioisotope production and service company. The company's staff combines over fourty years of commercial radioisotope manufacturing experience with a specialty in Strontium-82 production. The company has just finished construction of a radioisotope handling facility in Lubbock, TX which will provide a unique service to the Sr82/Rb82 generator community for generator refurbishment. In addition, MIT/Positron will begin providing Active Pharmaceutical Ingredient (API) grade Sr-82 in 2012, via recycling of Sr-82 from spent Sr-82/Rb-82 generators and production of Sr-82 from foreign suppliers. Manhattan Isotope has an exclusive license from Los Alamos National Laboratory for recycling of Sr-82 from spent Sr-82/Rb-82 generators.
For more information about Positron's radioisotope plans click here.
